IBEX Ltd Julie K. Casteel sells 11,677 shares

After the transaction, IBEX's chief sales/marketing officer directly held 100,594 common shares.

Available on EDGAR 11/10/2026 - 06:23 PM EST Accepted by SEC EDGAR 11/10/2026 - 06:23 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

IBEX Ltd's Chief Sales/Marketing Officer, Julie K. Casteel, sold 11,677 common shares on November 10, 2026, at a weighted average price of $50.7156 per share. The sale was reported as a direct transaction; afterward, she directly held 100,594 shares. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 11,677 shares

Net Sell 1 txn

Insider Casteel Julie K

Role Chief Sales/Marketing Officer

Sold 11,677 shs ($592K)

Share of Position Sold 10.4%

Type	Security	Shares	Price	Value
Sale	Common Shares F1	11,677	$50.7156	$592K

Holdings After Transaction: Common Shares — 100,594 shares (Direct)

Holdings Before and After: Common Shares, 112,271 to 100,594 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $50.32 to $51.22; the price reported above reflects the weighted average sales price. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Key Figures

Common shares sold: 11,677 shares Weighted average sale price: $50.7156 per share Trade price range: $50.32–$51.22 per share +1 more

4 metrics

Common shares sold 11,677 shares November 10, 2026

Weighted average sale price $50.7156 per share Multiple trades on November 10, 2026

Trade price range $50.32–$51.22 per share Prices for the reported sale

Direct shares held after transaction 100,594 shares Following the November 10, 2026 sale

Key Terms

weighted average sales price, open market or private transaction, Rule 10b5-1 plan

3 terms

weighted average sales price financial

"the price reported above reflects the weighted average sales price"

open market or private transaction financial

"Sale in open market or private transaction"

Rule 10b5-1 plan regulatory

"No Rule 10b5-1 plan is reported"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IBEX shares did Julie K. Casteel sell, and what did she hold afterward?

Julie K. Casteel, IBEX Ltd's Chief Sales/Marketing Officer, sold 11,677 common shares on November 10, 2026, at a weighted average of $50.7156 per share. The reported post-sale position was 100,594 directly held shares.

What price range did Julie K. Casteel's IBEX share sale cover?

The sale comprised multiple trades priced from $50.32 to $51.22, with $50.7156 reported as the weighted average sales price. Julie K. Casteel undertook to provide the issuer, any issuer security holder, or SEC staff with the number sold at each price upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Casteel Julie K

(Last) (First) (Middle)

C/O IBEX LIMITED

1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)

WASHINGTON DISTRICT OF COLUMBIA 20006

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Sales/Marketing Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/10/2026		S		11,677	D	$50.7156(1)	100,594	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $50.32 to $51.22; the price reported above reflects the weighted average sales price. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Remarks:

	Lisa Lenstrohm, Attorney-in-Fact	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)